Standardized, Microbiota-Based Investigational Live Biotherapeutic May Decrease Risk Of rCDI, Study Finds

October 05, 2021

Infectious Disease Advisor (10/4) reports on research finding that “a standardized, microbiota-based investigational live biotherapeutic, RBX2660, was found to consistently decrease the risk for recurrent Clostridioides difficile infections (rCDI).” The r...